New York Endocrinology

06/18/2026

You can’t have it both ways.
If GLP-1 medications improve cardiovascular disease, sleep apnea, fatty liver disease, kidney disease, diabetes, and many other obesity-related conditions, then we must acknowledge what connects them: obesity is a chronic disease.
For too long, obesity has been treated as a personal failure rather than a medical condition. Yet when we treat obesity effectively, we often see improvements across multiple organ systems.
The conversation shouldn’t be whether obesity is a disease.
The conversation should be how we diagnose it earlier, treat it better, and help patients achieve lasting health through body recomposition, nutrition, movement, and when appropriate, medication.

Also if you are going to say “well I don’t have obesity and it helped me with…”

If you did a body composition and SAW that your visceral fat is low and your percentage body fat was below 28 if you are woman or below 20% of you are a man, and good muscle@mass and used the medication and a disease improved, then I’ll give it to you.
But if you are just assuming you didn’t have visceral fat or a higher than normal percentage body fat and you felt great with the GLP1, well NEWSFLASH, you probably did have fat to lose and now you feel great.

06/18/2026

06/18/2026

A patient of mine lost 110 pounds in 16 months while losing only 15 pounds of muscle mass.
This is why I have spent years saying that the goal of GLP-1 therapy is not weight loss.
The goal is body recomposition.
Too many people focus only on the number on the scale and miss what really matters: preserving muscle while reducing excess body fat.
I wrote about this in Weightless, and it’s one of the reasons I built WeightlessAI.

WeightlessAI helps patients track their body composition with a simple phone scan and gives clinicians insights to make more informed recommendations based on what is actually changing inside the body; not just what the scale says.

Have you ever had your body composition measured while losing weight? 👇

06/17/2026

The moment I knew I had to build WeightlessAI wasn’t because AI became popular.
It was after receiving message after message from patients suffering side effects that I knew were often preventable.
Nausea.
Vomiting.
Constipation.
ER visits. 
Muscle loss.
Fear.
Not because the medications were bad.
But because patients weren’t being properly guided.
For years, I tried to solve this problem one patient at a time.
Then I wrote a book.
But I can’t force millions of people to read my book.
And I can’t personally answer every question from every patient or clinician.
That’s when I had my eureka moment.
What if I could take everything I’ve learned from 16+ years of prescribing GLP-1 medications and make it available 24/7?
What if every patient could have access to guidance between appointments?
What if every clinician had support when caring for patients on these medications?
That’s why I built WeightlessAI.
Because no patient should suffer from preventable side effects.
And no clinician should have to guess.
One expert is not enough.
But together, we can help millions.

July 15th.

06/17/2026

The future of GLP-1 therapy may include indications we can’t fully imagine today. Pregnancy may eventually be one of them.
But we’re not there yet.
Right now, millions of patients are taking GLP-1 medications, often without adequate education, body composition monitoring, nutritional guidance, or access to clinicians trained in obesity medicine.
Before we expand where these medications are used, we need to improve how they’re being used.
Patients deserve informed guidance.
Clinicians deserve better tools.
And obesity deserves the same level of expertise as every other chronic disease.
That’s one of the reasons I’m building WeightlessAI: to help bridge the gap between rapidly advancing science and real-world patient care.

July 15th.

06/16/2026

You don’t know how much this pains me.
Another side effect that can be, should be
PREVENTED!

I’ve been saying this for YEARS. I’ve made posts about it. How to prevent hypotension in a patient using a GLP1. It’s in my freaking book. But no, that wasn’t enough that I have to replicate my brain and brain process to be with YOU. Anytime, anywhere.

My mission is that patients are not used as guinea pigs, on you prescriber learning by trail and error. Hi 👋🏼 I have the expertise to help you with this. And instead of not sharing, keeping it just for my patients, I actually decided to do the opposite: to show you how to prescribe these medications. I wrote a book for you and your patients. And now, YOU will have access to my thought process in my patients when using a GLP1.

My mission is to HELP you, help your patients better.

And I’m also giving you, patient, access to my guidance that I give my patients.

The book, now the AI. NO MORE EXCUSES!

06/16/2026

I hear this everyday in my practice. Woman having written in them perimenopause but keep attributing to daily life stressors.

I am not saying those life stressors are not real, oh they are, and surely contributing to your symptoms. But I want you to think “mmm maybe it’s perimenopause”.

Because some life stressors are easy to fix, but perimenopause IS.

Don’t accept feeling 70% feeling good.
THERE IS HELP!

06/15/2026

For years, one of the biggest concerns around GLP-1 medications has been accidental exposure during early pregnancy.
This new meta-analysis of nearly 37,000 pregnancies found NO increased risk of major congenital malformations and even observed lower rates of preterm birth and adverse maternal outcomes.
Before we celebrate, remember: these were observational studies, not randomized clinical trials. But also remember, that most likely we will never have RCT trials on pregnant woman and GLP1. Most of what we will learn will be clinical observations.

The most important takeaway is not that GLP-1 medications are proven safe during pregnancy. But we can also say, that improved metabolism and healthier weight are beneficial for both the mother and her baby.
The takeaway is that accidental early exposure may pbe less concerning than previously feared.

For now, guidelines remain unchanged, and I continue to recommend stopping GLP-1 medications before a planned pregnancy.

Overall, this is encouraging data, but we will need more to recommend it in pregnancy.

Next month me and my team will present an abstract at the World Obesity Federation of a patient of mine that I used a GLP1 throughout her pregnancy with excellent results.

06/15/2026

30 days until launch.
When I immigrated to the United States at 25, I could never have imagined that one day I would write a national bestselling book and build an AI trained on my approach to obesity medicine.
For more than 16 years, I’ve helped patients navigate GLP-1 medications, body recomposition, menopause, diabetes, and metabolic health.
But one doctor can only reach so many people.
That’s why I built WeightlessAI.
Not to replace clinicians.
Not to replace human connection.
But to help patients make better decisions between visits and help clinicians deliver safer, more personalized care.
My dream has never been to help thousands.
My dream has always been to help millions.
July 15, 2026.
We’re almost there. ❤️

06/13/2026

Many of you sent me this video.
While I agree that our industry plays a BIG, majoritarian part on our current obesity problem, ITS NOT THE ONLY ONE.
There are things that can easily modifiable and others that will take generations to get rid off, and that’s the food industry.
The damage of our current food industry has left transgenerational damage. That will take generations to fix.
My problem with people like her or other many, many that criticize GLP1 medications, are the ones that the medication threatens their agenda. When you hear someone criticizing, specially if they are known in the wellness biz, they sell some supplement, some program, some coaching that probably will end when patients improve with GLP1.